Dennis Keefe
Company: Complement Therapeutics
Job title: Chief Scientific Officer
Seminars:
Panel Discussion: Discussing the Next-Generation of Novel Modalities to be Used for Enhanced Delivery & Broader Impact in CNS & Ophthalmic Indications 12:30 pm
Addressing the critical challenge of achieving sufficient complement inhibitor exposure in the CNS, a major reason for past failures with peripherally acting drugs Exploring novel delivery modalities like gene therapy, shuttle technologies that are in early development, to unlock the therapeutic potential of complement inhibition neurodegenerative diseases Highlighting the significant appeal and ongoing development of…Read more
day: Conference Day Two
Panel Discussion: Understanding the Current Attitudes Towards Mandatory Vaccinations Before Dosing a Patient with Complement Inhibitors 4:00 pm
Re-evaluating the blanket vaccination requirements for complement inhibitors considering the emergence of novel, non-C5 complement inhibitors that show a lower infection risk compared to earlier C5 antibodies Discussing whether a blanket-approach remains justified, or whether a more nuance, risk stratified approach is warranted Navigating vaccination in acute vs chronic complement-mediated conditions, to mitigate infection risk…Read more
day: End of Day Two
Rethinking the Delivery of Complement-Based Therapeutics to Ensure Complement Moderators are Reaching the Correct Targets in the Appropriate Quantities 2:30 pm
Join this workshop to deepen your understanding of the approaches being used to overcome the challenges in effectively delivering complement mediators to their target tissues and discuss optimal dosages for complement-based therapeutics for different organs. Understanding organ-specific differences and their implications for developing effective complement targeted therapies from a drug delivery perspective Exploring alternatives to…Read more
day: Pre-Conference Workshop Day